Monday, December 9, 2024

FDA Grants Approval for Resistant Hypertension Management to Idorsia’s Tryvio

Similar articles

The recent approval by the US Food and Drug Administration (FDA) marks a significant milestone in the realm of resistant hypertension management, as Idorsia Ltd’s innovative drug Tryvio (aprocitentan) has received the green light for addressing the needs of adults whose blood pressure remains uncontrolled despite undergoing treatment with other antihypertensive medications. Tryvio stands out as an endothelin receptor antagonist, exerting its therapeutic effects by interfering with the binding process of endothelin (ET)-1 to both ETA and ETB receptors. This mechanism of action holds promise in offering a novel approach to managing resistant hypertension by targeting the endothelin pathway, which plays a crucial role in regulating vascular tone and blood pressure.
With this approval, Tryvio emerges as a potential game-changer in the landscape of resistant hypertension therapeutics, providing clinicians with an additional tool to effectively address the challenges posed by inadequately controlled blood pressure in certain patient populations.
Jean-Paul Clozel, MD, the Chief Executive Officer of Idorsia, underscored the importance of the FDA’s approval of Tryvio, emphasizing the widespread problem of uncontrolled hypertension despite the availability of current treatments. This persistent issue significantly heightens the risk of cardiovascular and cerebrovascular events, highlighting the urgent need for innovative therapeutic solutions.

Idorsia’s Tryvio Targets Unmet Needs in Hypertension, Pioneering a New Treatment Pathway

Idorsia’s development of aprocitentan was specifically geared towards tackling this challenge, with a dedicated clinical program aimed at addressing the needs of patients who continue to experience high blood pressure despite receiving multiple antihypertensive medications at optimal doses. This strategic approach reflects Idorsia’s commitment to advancing the field of resistant hypertension management and improving outcomes for patients facing this medical dilemma.

Subscribe Weekly Market Access News

* indicates required

Hypertension stands as a primary contributor to cardiovascular disease, affecting approximately 10% of the estimated 1.3 billion individuals with hypertension globally. Among them, a significant portion grapples with difficult-to-control hypertension even with the use of multiple medications.

Until the approval of Tryvio, there existed no FDA-approved systemic antihypertensive therapies targeting the ET pathway. Current treatment options for resistant hypertension primarily focus on regulating salt and water, antagonizing the renin–angiotensin–aldosterone system, reducing extracellular calcium influx into cells, sympatholytic activity, or non-selective vasodilatory effects.

Resistant Hypertension

FDA Clears Tryvio After PRECISION Trial: A Milestone for Resistant Hypertension Care

The FDA’s decision to approve Tryvio was based on data from the Phase III PRECISION trial, which evaluated the short- and long-term efficacy of Tryvio in 730 patients with difficult-to-control hypertension across a three-part study. During the trial, Tryvio consistently demonstrated reductions in sitting systolic blood pressure (SBP) compared to placebo, meeting both primary and secondary efficacy endpoints.

Furthermore, Tryvio exhibited consistent efficacy across various patient subgroups, including sex, age, body mass index, race, and geographic area. Treatment-emergent adverse events (AEs) were reported in a higher percentage of patients administered Tryvio compared to placebo, with mild-to-moderate fluid retention being the most frequently observed AE.

PRECISION trial investigator Michael A. Weber, MD, highlighted the significance of Tryvio’s approval in addressing the unmet need for effective resistant hypertension management in high-risk patients. He emphasized the transformative progress offered by Tryvio, marking the first oral antihypertensive agent in over three decades to target a new therapeutic pathway. Tryvio’s once-daily oral dosing regimen, coupled with its compatibility with other prescribed medications and minimal drug-drug interactions, presents a promising option for both physicians and patients grappling with uncontrolled hypertension.

 

Resource: Pharmexec, March 20, 2024

You can follow our news on our Telegram, LinkedIn and Youtube accounts.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article